YAP1 and non-small cell lung carcinoma: Similarly, another study discovered that the increased expression of YAP in EGFR-mutated NSCLC cells led to resistance to EGFR-TKI (erlotinib), whereas the knockdown of YAP increased the sensitivity of NSCLC cells to erlotinib [99].